FY2021 EPS Estimates for Syros Pharmaceuticals, Inc. Cut by Oppenheimer Holdings (SYRS)
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Oppenheimer Holdings lowered their FY2021 EPS estimates for shares of Syros Pharmaceuticals in a report issued on Wednesday. Oppenheimer Holdings analyst L. Cann now anticipates that the company will post earnings per share of $1.07 for the year, down from their previous forecast of $1.10.
A number of other analysts have also recently weighed in on SYRS. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 target price on shares of Syros Pharmaceuticals in a report on Tuesday, October 31st. Wedbush restated an “outperform” rating and set a $22.84 target price (down previously from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. JMP Securities cut Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Finally, Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $26.14.
TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/10/fy2021-eps-estimates-for-syros-pharmaceuticals-inc-cut-by-oppenheimer-holdings-syrs.html.
Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded down $0.28 during midday trading on Friday, hitting $11.34. The company had a trading volume of 88,573 shares, compared to its average volume of 90,089. Syros Pharmaceuticals has a twelve month low of $10.22 and a twelve month high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting analysts’ consensus estimates of ($0.53).
Institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors grew its holdings in shares of Syros Pharmaceuticals by 249.8% in the second quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock valued at $113,000 after acquiring an additional 5,016 shares in the last quarter. Bank of New York Mellon Corp raised its position in Syros Pharmaceuticals by 17.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock worth $520,000 after purchasing an additional 5,305 shares during the period. New York State Common Retirement Fund raised its holdings in shares of Syros Pharmaceuticals by 167.9% in the second quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock worth $216,000 after buying an additional 8,399 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Syros Pharmaceuticals during the third quarter worth $133,000. Finally, Ark Investment Management LLC boosted its position in Syros Pharmaceuticals by 114.7% during the second quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock worth $285,000 after acquiring an additional 9,460 shares during the last quarter. 59.76% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Richard A. Young sold 3,282 shares of the business’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $22.00, for a total transaction of $72,204.00. Following the sale, the director now owns 420,101 shares in the company, valued at approximately $9,242,222. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 33.60% of the stock is owned by insiders.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.